Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Receives CE Mark for ePlex BCID Gram-Positive and Gram-Negative Panels

NEW YORK (GenomeWeb) – GenMark Diagnostics said after the market closed on Thursday that it has achieved CE marking for its ePlex BCID gram-positive and gram-negative panels.

The firm noted that with CE marking for the BCID-GP and BCID-GN panels, it has achieved the designation for its ePlex family of sepsis panels, which also includes the BCID Fungal Pathogen Panel that achieved the CE mark in April.

"This rounds out our family of ePlex bloodstream infection assays, which we've designed to offer the broadest pathogen inclusivity and drug resistance markers of any multiplex molecular solution on the market today," Hany Massarany, president and CEO of GenMark, said in a statement. He said that GenMark believes the three BCID panels "will have a significant impact on the management of a critical disease state, while bringing clinical, economic, and quality benefits to ePlex customers and their patients."

Earlier this month, GenMark received 510(k) clearance from the US Food and Drug Administration for its ePlex instrument and Respiratory Pathogen Panel, which detects more than 20 viral and bacterial pathogens that commonly cause upper respiratory infections.

It also increased the size of a previously announced public offering to 6,382,978 shares of its common stock priced at $11.75 per share. The gross proceeds to GenMark, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be about $75.0 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more